1. Biologic Medications for Severe Asthma: Implications for Understanding Pathogenic Heterogeneity and Endotypes.
- Author
-
Ramonell RP, Gauthier MC, Ray A, and Wenzel SE
- Subjects
- Humans, Antibodies, Monoclonal, Humanized therapeutic use, Omalizumab therapeutic use, Phenotype, Antibodies, Monoclonal therapeutic use, Severity of Illness Index, Infliximab therapeutic use, Adalimumab therapeutic use, Asthma drug therapy, Asthma immunology, Biological Products therapeutic use, Anti-Asthmatic Agents therapeutic use
- Abstract
Asthma is a chronic inflammatory disease of the airways long known for phenotypic heterogeneity. Phenotyping studies in asthma have led to a better characterization of disease pathogenesis, yet further work is needed to pair available treatments with disease endotypes. In this review, the biology of targeted pathways is discussed along with the efficacy of biologic therapies targeting those pathways. Results of asthma clinical trials are included, as well as results of trials in related diseases. This review then analyzes how biologics help to inform the complex immunobiology of asthma and further guide their use while identifying areas for future research.
- Published
- 2025
- Full Text
- View/download PDF